<DOC>
	<DOCNO>NCT02260622</DOCNO>
	<brief_summary>Background : Up 10 % patient peripheral arterial disease ( PAD ) develop critical limb ischemia ( CLI ) decrease blood flow artery limb . CLI result rest pain , ulcer , gangrene , limb loss . The outcome patient CLI poor . Within 3 month onset , 12 % patient require amputation ( removal part limb ) 9 % die major cardiovascular event ( heart attack stroke ) . Percutaneous angioplasty ( PTA ) , procedure use open blockage blood flow , become first-line treatment CLI give effectiveness , low cost , low risk complication . However , 40 % patient re-narrowing artery ( restenosis ) follow PTA procedure . This thought happen part due build blood cell call platelet also lead formation blood clot . In order try avoid problem , patient prescribe combination two blood thin medication , acetylsalicylic acid ( ASA aspirin ) clopidogrel ( brand name Plavix ) . The purpose study determine new blood thinner call rivaroxaban , give combination aspirin , would effective prevent re-narrowing artery current standard care ( aspirin clopidogrel ) . Rivaroxaban pill require blood test monitoring . It approve Health Canada use prevention blood clot patient undergo hip knee surgery treat patient blood clot legs lung . Low dose aspirin approve reduce risk heart attack stroke . These medication test together patient prevention re-narrowing artery This pilot study conduct one center , The Ottawa Hospital . It Phase 2 open label randomize control trial . Following PTA procedure , inclusion/exclusion criterion meet , participant randomize one two group : 1 . Rivaroxaban 2.5 mg BID X 90 day plus ASA 81 mg daily OR 2 . Clopidogrel 75 mg daily X 90 day plus ASA 81 mg daily Visits occur 7 day , 30 day , 90 day , 6 month 12 month . Participants follow 12 month ( ± 14 day ) total . All adverse event collect duration study .</brief_summary>
	<brief_title>Pilot Study Examine Use Rivaroxaban After Angioplasty Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>1 . Written informed consent . 2 . Infrainguinal PAD present CLI define Rutherford category 3 , 4 , 5 3 . More 50 % stenosis target infrainguinal vessel 4 . Good candidate PTA use POBA ( plain old balloon angioplasty ) without stenting define TASC b lesion . 1 . Rutherford scale 0,1,2 6 2 . Acute limbthreatening ischemia ( e.g . embolic disease ) 3 . Previous infrainguinal bypass PTA procedure affect leg 4 . Hybrid procedure 5 . Creatinine clearance &lt; 30 mL/min 6 . Platelet count &lt; 100x109/L 7 . INR &gt; 1.5 ; Hbg &lt; 100 g/L 8 . History condition associate increase bleed risk include , limited : 1 . Major surgical procedure trauma within 30 day randomization visit 2 . Clinically significant gastrointestinal bleeding within 6 month randomization visit 3 . History intracranial , intraocular , spinal , atraumatic intraarticular bleed 4 . Chronic hemorrhagic disorder 5 . Known intracranial neoplasm , arteriovenous malformation , aneurysm 6 . Sustained uncontrolled hypertension : systolic blood pressure ≥180 mmHg diastolic blood pressure ≥100 mmHg 9 . Severe , disable stroke ( modify Rankin score 4 5 , inclusive ) within 3 month stroke within 14 day randomization visit 10 . Aspirin combination thienopyridines within 5 day randomization 11 . Intravenous antiplatelets within 5 day randomization 12 . Fibrinolytics within 10 day randomization 13 . Known HIV infection time screen 14 . Known significant liver disease ( e.g. , acute clinical hepatitis , chronic active hepatitis , cirrhosis ALT &gt; 3ULN ) 15 . Childbearing potential without proper contraceptive measure , pregnancy breast feeding 16 . Drug addiction alcohol abuse within 12 month randomization visit 17 . Systemic treatment strong CYP 3A4 Pglycoprotein inhibitor : ketoconazole , itraconazole , posaconazole , ritonavir 18 . Known allergy hypersensitivity component rivaroxaban , ASA clopidogrel 19 . Need long term anticoagulation double antiplatelet agent PAD atrial fibrillation , heart valve replacement , acute coronary syndrome , stroke venous thromboembolism 20 . Anticipated need chronic ( &gt; 4 week ) therapy nonsteroidal antiinflammatory drug . 21 . Concomitant treatment anticoagulant , include oral anticoagulant , warfarin , dabigatran , apixaban , except circumstance switch therapy study treatment . 22 . Inability adhere protocol . 23 . Severe concomitant condition disease ( e.g . life expectancy &lt; 6 month secondary cancer , advance liver disease dementia )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Restenosis</keyword>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Infrainguinal Percutaneous Transluminal Angioplasty</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>